Quick Links

Accreditation/Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Clovis Oncology, Inc. and Myriad Genetics, Inc.

Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP Inhibitors

Release Date: September 29, 2017
Expiration Date: September 29, 2018
Media: Internet - based


Activity Overview

The treatment landscape for ovarian cancer has changed substantially with the introduction of poly (ADP-ribose) polymerase (PARP) inhibitor therapy. It is important for clinicians who treat patients with ovarian cancer to have a solid understanding of the mechanistic rationale for the use of these medications in order to optimize their therapeutic application. Other challenges associated with maximizing therapeutic outcomes with PARP inhibitor use include selection of optimal testing strategies to personalize care, management of treatment-related toxicities, and development of evidence-based sequencing and combination strategies.

This educational activity, featuring leading experts in the treatment of patients with ovarian cancer, was developed to help clinicians with the management of these challenges. Multiple topics pertaining to the use of PARP inhibitors in the treatment of ovarian cancers will be explored through a combination of didactic reviews of key data and short video interviews with the faculty addressing important clinical practice points.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Clovis Oncology, Inc. and Myriad Genetics, Inc.

CME/CE Activity Table of Contents

  • Module A: Overview of Ovarian Cancer and Unmet Clinical Needs
  • Module B: Assessing Methods to Optimize Personalized Care in Ovarian Cancer
  • Module C: Current Methods and Future Directions to Optimize PARP Inhibition in Multiple Lines of Care
  • Module D: Management of Treatment-Related Toxicities Posttest

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a cme/ce certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a cme/ce certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of ovarian cancers and other emerging tumor targets. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with ovarian cancers may also participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

  • Describe how PARP inhibition strategies have been applied to the management of recurrent ovarian cancer
  • Discuss how care can be personalized via the use of testing strategies in BRCA-mutated and non‒BRCA-mutated patient populations with ovarian cancer
  • Examine PARP inhibitor mechanisms in the context of treatment resistance and emerging role in the maintenance setting
  • Describe effective strategies to proactively plan for and manage treatment-related toxicities in the setting of ovarian cancer

Faculty, Staff, and Planners' Disclosures


Robert L. Coleman, MD, FACOG, FACS
Professor, Vice Chair of Clinical Research
Ann Rife Cox Chair in Gynecology
Department of Gynecologic Oncology and Reproductive Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosure: Grant/ Research Support: Array BioPharma, AstraZeneca, Clovis Oncology, EMD Serono, Gradalis, Janssen, Merck; Consultant: AbbVie, Debiopharm, Genmab, ImmunoGen, Merrimack, Navigant Consulting, Perthera, Vaniam Group, LLC, Verastem; Speakers Bureau: AstraZeneca, BioAscend, Roche; Advisory Boards: AstraZeneca, Bayer Healthcare, Inc., Caris Life Sciences, Cerulean, Clovis Oncology, Gamamabs, Incyte, Janssen, Novocure, Pfizer, Precision Oncology, Roche, Tesaro


Deborah K. Armstrong, MD
Professor of Oncology
Professor of Gynecology and Obstetrics
Johns Hopkins Kimmel Cancer Center
Baltimore, MD

Disclosure: Grant/ Research Support: AstraZeneca, Clovis; Consultant: Cue Biopharma

Michael J. Birrer, MD, PhD
Professor, Harvard Medical School
Director, Gynecologic Medical Oncology
Massachusetts General Hospital Cancer Center
Boston, MA

Disclosure: No relevant financial relationships with commercial interests to disclose.

Maurie Markman, MD
President, Medicine & Science
Cancer Treatment Centers of America
Clinical Professor of Medicine
Drexel University College of Medicine
Philadelphia, PA

Disclosure: Speakers Bureau: Clovis Oncology, Tesaro, AstraZeneca

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

CME/CE Provider Contact Information

Physicians’ Education Resource®, LLC
2 Clarke Drive
Suite 110
Cranbury, NJ 08512

Hardware And Software Requirements 

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Filter By